Research Faculty

Burk Jubelt, MD

Burk Jubelt, MD
Appointed 04/01/89
5820 Upstate University Hospital - Downtown Campus
750 East Adams Street
Syracuse, NY 13210

315 464-8668

Current Appointments

Hospital Campus

  • Downtown

Clinical Section Affiliations

  • Neurology: Multiple Sclerosis/Neuro-Immunology

Research Programs and Affiliations

  • Biomedical Sciences Program
  • Neurology
  • Neuroscience Program
  • Research Pillars


Web Resources

Education & Fellowships

  • Fellowship: Johns Hopkins University School of Medicine, 1979, Virology/Immunology
  • Residency: Presbyterian Hospital, Columbia University, 1976
  • MD: University of Kansas School of Medicine, 1972

Previous Appointments

  • Northwestern University Medical School, 1979–1989

Clinical Interests

  • Immune Response to CNS virus infections; Growth Factors for Post-Polio Syndrome; Immune-mediated diseases; Treatment of Multiple Sclerosis

Education Interests

  • How to take an accurate Neurological History;  How to do an accurate Neurological Exam; MRI scans

Research Interests

  • CNS acute and chronic polio- and entero-virus infections; Growth factors for Post-Polio Syndrome; Treatment of Multiple Sclerosis; Amyotrophic Lateral Sclerosis (ALS) Motor Neuron Gene Expression

Clinical Trials

  • A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis
    Read more
  • A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis
    Read more

Specialties & Certification

  • Neurology

Diseases & Conditions Treated

  • Multiple Sclerosis (MS)
  • Post Polio Syndrome


  • Adults


  • American Academy of Neurology (AAN)
  • American Neurological Association

Current Hospital Privileges

  • Upstate University Hospital
  • Crouse Hospital
  • VA Medical Center

HealthLinkOnAir Radio Interview

2/27/13 Research study to develop a new medical treatment for multiple sclerosis (MS)

Web Resources

Research Abstract

Post-Polio Syndrome(PPS) in the Mouse.  We have developed a model of PPS in the mouse in order to analyze pathogenesis and try different modalities of treatment.  The growth factors GDNF and IGF1 have resulted in improved strength of the Post-Polio mouse.  

Amyotrophic Lateral Sclerosis (ALS) Motor Neuron Gene Expression. Motor neurons have been isolated from autopsy spinal cords of ALS patients and controls. RNA has been isolated from these motor neurons and cDNA libraries have been constructed. Subtraction of these libraries has begun in an attempt to identify motor neuron specific genes and gene products.

Multiple Sclerosis Treatment.  Mechanisms of action of present MS disease modifying agents.  Development of new disease modifying agents.


1.  Christophi GP, Christophi JA, Gruber RC, Mihai C, Mejico LJ, Jubeltb.  Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-B 1a treated multiple sclerosis patients.  J Nourol Sci 2011; 307: 41-45.

2.  Jubelt B, Mihai C, Li TM, Veerapaneni P. Rhombencephalitis / Brainstem Encephalitia.  Curr Neurol Neurosci Rep 2011; 11:

3. Kister I et al.  Rapid disaese course in African Americans with multiple sclerosis.  Neurology 2010; 75: 217-223.

4.  Jubelt B et al. Retrograde viral delivery of GDNF and IGF1 prevents the development of late weakness (Post-Polio Syndrome) in a mouse model. Neurology 2009 (suppl 3):A362.

Clinical Profile Shortcut:
Faculty Profile Shortcut: